Conn Bay (600572.SH): Cumulative repurchase of 51.45 million shares of the company
Glonghui, May 5, 丨 Conn Bay (600572.SH) announced that as of April 30, 2024, the company had repurchased a total of 51.46.45 million shares of the company's shares through centralized bidding transactions at the Shanghai Stock Exchange, accounting for 2.00% of the company's total share capital. The highest repurchase transaction price was 5.00 yuan/share, the lowest price was 4.08 yuan/share, and the total capital commission used was 245.9663 million yuan (excluding transaction fees such as stamp duty and transaction fees).
Conn Bay (600572.SH)'s net profit of 216 million yuan in the first quarter decreased by 23.98% year-on-year
On April 26, Ge Longhui (600572.SH) released its report for the first quarter of 2024. Operating revenue for the reporting period was 1,824 million yuan, a year-on-year decrease of 14.38%; net profit attributable to shareholders of listed companies was 216 million yuan, a year-on-year decrease of 23.98%; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 201 million yuan, a year-on-year decrease of 23.57%; and basic earnings per share were 0.084 yuan.
Conn Bay (600572.SH) announced its 2023 annual results, with net profit of 592 million yuan, an increase of 65.19%
Conn Bay (600572.SH) released its 2023 annual report. The company's revenue was 6.733 billion yuan...
Are Strong Financial Prospects The Force That Is Driving The Momentum In Zhejiang CONBA Pharmaceutical Co.,Ltd.'s SHSE:600572) Stock?
Zhejiang CONBA PharmaceuticalLtd (SHSE:600572) has had a great run on the share market with its stock up by a significant 10% over the last three months. Since the market usually pay for a company's
Conn Bay (600572.SH) has repurchased a total of 1% of its shares at a cost of 120 million yuan
Conn Bay (600572.SH) announced that as of March 29, 2024, the company passed the Shanghai Stock Exchange...
The controlling shareholders of Kangenbei (600572.SH) increased their total shares by 2%
Conn Bay (600572.SH) issued an announcement from January 31, 2024 to March 22, 2024...
Zhejiang CONBA Pharmaceutical Co.,Ltd.'s (SHSE:600572) Shares Lagging The Market But So Is The Business
When close to half the companies in China have price-to-earnings ratios (or "P/E's") above 32x, you may consider Zhejiang CONBA Pharmaceutical Co.,Ltd. (SHSE:600572) as an attractive investment with i
Conn Bay (600572.SH): Accumulated cost of 884.53 million yuan to buy back 0.75% of shares
Glenn Bay (600572.SH) announced on March 1, 2024, that as of February 29, 2024, the company had repurchased a total of 19.2432.92 million A-shares through centralized bidding transactions on the Shanghai Stock Exchange, accounting for 0.75% of the company's total share capital of 257,00373.19 million shares. The highest price of the repurchase transaction was RMB 4.90 yuan/share, the lowest price was RMB 4.08 per share, and the total capital used was RMB 88.4530 million.
Investors Five-year Losses Continue as Zhejiang CONBA PharmaceuticalLtd (SHSE:600572) Dips a Further 4.8% This Week, Earnings Continue to Decline
Ideally, your overall portfolio should beat the market average. But in any portfolio, there will be mixed results between individual stocks. So we wouldn't blame long term Zhejiang CONBA Pharmaceuti
Kangenbei (600572.SH): Assets such as land use rights and ground attachments in the old factory area of the Jiangxi subsidiary are stored by the government
Kang Enbei (600572.SH) announced that in response to the decision of the Yiyang County Government in Jiangxi Province to recover idle land assets,...
The controlling shareholder of Kangenbei (600572.SH) increased its holdings by 7.02 million shares
Zhitong Finance App News, Connbei (600572.SH) announced that on January 31 and February 1, 2024, Zhejiang Traditional Chinese Medicine and Health Industry Group Co., Ltd. (abbreviation: Provincial Traditional Chinese Medicine and Health Industry Group), the controlling shareholder of the company increased its holdings by 7.02 million shares through centralized bidding transactions at the Shanghai Stock Exchange, accounting for 0.27% of the company's total share capital, with an average increase of 4.52 yuan/share, with a total increase of RMB 31.751 million.
Conn Bay (600572.SH): It has spent 38.2082 million yuan to buy back a total of 8,3290.5 million A shares of the company
GLONGHUI, January 31 | Conn Bay (600572.SH) announced that as of January 31, 2024, the company had repurchased a total of 83290.5 million A-share shares through the Shanghai Stock Exchange trading system, accounting for 0.32% of the company's total share capital of 257,00373.19 million shares. The highest price of the repurchase transaction was RMB 4.70 yuan/share, and the lowest price was RMB 4.47 yuan/share. The total amount of capital paid was RMB 38.2082.29 million (excluding tax, trading commissions, etc.) costs).
Conn Bay (600572.SH): Initial repurchase of 5.4718 million A-shares
Glonghui, January 29丨Conn Bay (600572.SH) announced that on January 29, 2024, the company repurchased 5.4718 million A-shares for the first time through the Shanghai Stock Exchange trading system, accounting for 0.21% of the company's total share capital of 257,00373.19 million shares. The highest price of the repurchase transaction was RMB 4.7 yuan/share, the lowest price was RMB 4.57 per share, and the total capital paid was RMB 25.265.3 million (excluding transaction fees such as stamp duty and transaction fees).
Zhejiang CONBA Pharmaceutical Co.,Ltd.'s (SHSE:600572) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
With its stock down 12% over the past month, it is easy to disregard Zhejiang CONBA PharmaceuticalLtd (SHSE:600572). But if you pay close attention, you might gather that its strong financials could
Conn Bay (600572.SH): Plans to publicly list at least 26 million yuan to transfer 20% of the shares in online companies
On December 28, Ge Longhui (600572.SH) announced that in order to continuously adjust and optimize resource allocation and focus on developing the company's core business in the traditional Chinese medicine health industry, the company plans to transfer 20% of the shares held by the participating company Shanghai Kede Network Technology (Group) Co., Ltd. (hereinafter referred to as Kede Network Company, target company) through a public listing on the Zhejiang Property Exchange. According to the asset evaluation results as of October 31, 2023, the assessment value of all shareholders' equity of Kede.com is 127,546,900 yuan (RMB, same below), and the company holds 20 of Kede.com
Kang Enbei (600572.SH): Ying Chunxiao resigns as co-chairman and other positions
Kang Enbei (600572.SH) issued an announcement. Ying Chunxiao applied to the company's board of directors to resign due to job adjustments...
Individual Investors Invested in Zhejiang CONBA Pharmaceutical Co.,Ltd. (SHSE:600572) Copped the Brunt of Last Week's CN¥617m Market Cap Decline
Key Insights Zhejiang CONBA PharmaceuticalLtd's significant individual investors ownership suggests that the key decisions are influenced by shareholders from the larger public 50% of the business i
Wu Han of Zhongkang Technology: The key to solving the development problems of the traditional Chinese medicine industry is to break the “island effect”
The first Traditional Chinese Medicine Ecological Conference is expected to bring new opportunities and perspectives to enterprise development and industrial upgrading.
What is the effect of Connbay's “exclusive proprietary Chinese medicine” price reduction and “four losses, four compensation”
“Investor Network” Cai Jun Kang Enbei (600572.SH, hereinafter referred to as the “Company”)'s exclusive proprietary Chinese medicine has been reduced on the Internet. Focusing on the main Chinese medicine health business, in the first three quarters of this year, Connberg's operating income and net profit attributable to shareholders of listed companies were 5.184 billion yuan and 623 million yuan respectively, up 15.51% and 171.76% year on year, respectively. The reason for the sharp increase in the company's net profit is related to two foreign investments. In the same period, the company withheld 510 million yuan in non-net profit, up 15.23% year on year. The reason behind the increase in performance is that the company has fallen into a trough in the past. After that, the company adjusted prescriptions
Connbay (600572.SH): Subsidiary drugs included in the “2023 edition of the National Health Insurance Catalogue” through negotiations
Gelonghui (600572.SH) announced that on December 13, 2023, the National Medical Security Administration and the Ministry of Human Resources and Social Security issued the “Notice on Issuance” (Health Insurance Development [2023] No. 30). According to this notice, the company's wholly-owned subsidiary Hangzhou Kangenbei Pharmaceutical Co., Ltd. (abbreviation: Hangzhou Kangenbei)'s innovative traditional Chinese medicine hollyhock total flavonoid oral patch was included in the “National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance<国家基本医疗保险、工伤保险和生育保险药品目录 (2023年) >” through negotiations Drug catalogue (2023)
No Data